Literature DB >> 15791443

Quantification of disease activity in patients undergoing leucocyte scintigraphy for suspected inflammatory bowel disease.

Heok K Cheow1, Demetrius D Voutnis, John W Evans, Katy R Szczepura, E Anna Swift, Nicholas J Bird, Prina Ruparelia, Chandra K Solanki, James R Ballinger, Edwin R Chilvers, Stephen J Middleton, A Michael Peters.   

Abstract

PURPOSE: Whole-body gamma camera counting is an alternative to faecal 111In collection for quantifying disease activity in inflammatory bowel disease (IBD) but requires administration of imaging activities of 111In. The aim of this study was to explore a dedicated whole-body counter which requires 20-fold less activity than gamma camera counting.
METHODS: Thirty patients with known or suspected IBD received 99mTc-granulocytes (approximately 200 MBq) and 111In-granulocytes (approximately 0.5 MBq). The 99mTc-cells were injected 45 min after the 111In-cells and immediately after a baseline 111In whole-body count. The decay-corrected count at 120 h was expressed as a fraction of baseline to give whole-body 111In retention (WBR). One patient was excluded as the injected cells were non-viable.
RESULTS: Median 45-min intravascular 111In recovery was 35% in patients compared with 43% in six normal volunteers (p<0.05). WBR in normals ranged from 91% to 93% and in 11 patients with negative 99mTc imaging from 87% to 96%. Only one of 11 patients with negative imaging had WBR <90% while 11/12 patients with WBR <90% had abnormal imaging. Ten of 13 patients with Crohn's disease (CD) had abnormal imaging. The lowest WBR in these ten was 77% and six had values of >90%. There was a significant association between WBR and 99mTc image grade (Rs=0.73, p<0.002) in 16 patients without CD, but not in 13 patients with CD (Rs=0.54, p>0.05).
CONCLUSION: Dedicated whole-body counting is able to quantify disease activity in IBD but may give normal values in active CD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15791443     DOI: 10.1007/s00259-004-1617-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

1.  Indium-111 labelled granulocyte scanning to detect inflammation in the lungs of patients with chronic sputum expectoration.

Authors:  D C Currie; A M Peters; N D Garbett; P George; B Strickland; J P Lavender; P J Cole
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

2.  Indium-111 autologous leucocyte scanning: comparison with radiology for imaging the colon in inflammatory bowel disease.

Authors:  S H Saverymuttu; A M Peters; H J Hodgson; V S Chadwick; J P Lavender
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-24

3.  Fluticasone propionate in Crohn's disease.

Authors:  M C de Kaski; A M Peters; J P Lavender; H J Hodgson
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

4.  Indium-111 whole-body retention: a method for quantification of disease activity in inflammatory bowel disease.

Authors:  M Carpani de Kaski; A M Peters; D Knight; A W Stuttle; J P Lavender; H J Hodgson
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

5.  Neutrophil kinetics in man.

Authors:  J T Dancey; K A Deubelbeiss; L A Harker; C A Finch
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

6.  Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis.

Authors:  D C Currie; S H Saverymuttu; A M Peters; S G Needham; P George; D P Dhillon; J P Lavender; P J Cole
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

7.  Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label.

Authors:  J Schölmerich; E Schmidt; C Schümichen; P Billmann; H Schmidt; W Gerok
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

8.  Prospective comparative study of technetium-99m-WBCs and indium-111-granulocytes for the examination of patients with inflammatory bowel disease.

Authors:  J W Arndt; A van der Sluys Veer; D Blok; G Griffoen; H W Verspaget; C B Lamers; E K Pauwels
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

9.  Imaging of inflammation with indium-111 tropolonate labeled leukocytes.

Authors:  A M Peters; S H Saverymuttu; H J Reavy; H J Danpure; S Osman; J P Lavender
Journal:  J Nucl Med       Date:  1983-01       Impact factor: 10.057

10.  Clinical relevance of activity parameters in Crohn's disease estimated by the faecal excretion of 111In-labeled granulocytes.

Authors:  W Fischbach; W Becker
Journal:  Digestion       Date:  1991       Impact factor: 3.216

View more
  5 in total

Review 1.  Role of scintigraphy in inflammatory bowel disease.

Authors:  Maria I Stathaki; Sophia I Koukouraki; Nikolaos S Karkavitsas; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

2.  Quantification of neutrophil migration into the lungs of patients with chronic obstructive pulmonary disease.

Authors:  Prina Ruparelia; Katherine R Szczepura; Charlotte Summers; Chandra K Solanki; Kottekkattu Balan; Paul Newbold; Diana Bilton; A Michael Peters; Edwin R Chilvers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

3.  Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.

Authors:  Federico Caobelli; Laura Evangelista; Natale Quartuccio; Demetrio Familiari; Corinna Altini; Angelo Castello; Mariapaola Cucinotta; Rossella Di Dato; Cristina Ferrari; Aurora Kokomani; Iashar Laghai; Riccardo Laudicella; Silvia Migliari; Federica Orsini; Salvatore Antonio Pignata; Cristina Popescu; Erinda Puta; Martina Ricci; Silvia Seghezzi; Alessandro Sindoni; Martina Sollini; Letterio Sturiale; Anna Svyridenka; Vittoria Vergura; Pierpaolo Alongi
Journal:  World J Radiol       Date:  2016-10-28

4.  Ulcerative Colitis Activity Presenting as Fever of Unknown Origin, in a Patient with Longstanding Disease under Continuous Treatment with Mesalazine.

Authors:  Panagiota Voukelatou; Elissavet Sfendouraki; Theodoros Karianos; Sofia Saranti; Dimitrios Tsitsimelis; Ioannis Vrettos; Andreas Kalliakmanis
Journal:  Case Rep Med       Date:  2016-07-18

5.  Accuracy of 99mTc (V)-Dimercaptosuccinic Acid Scintigraphy and Fecal Calprotectin Compared with Colonoscopy in Localizing Active Lesions in Inflammatory Bowel Disease.

Authors:  Vahid Basirat; Zahra Azizi; Sanam Javid Anbardan; Mina Taghizadeh Asl; Yasaman Farbod; Azam Teimouri; Nasser Ebrahimi Daryani
Journal:  Middle East J Dig Dis       Date:  2016-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.